New blood test aims to predict who will respond to immunotherapy
NCT ID NCT07155811
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100 adults with advanced solid tumors starting immunotherapy at one center in France.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VIDAS® STIMM™ T RUO test (a blood test that measures T-cell function)
- What this could lead to
- If successful, this test could help doctors predict which patients will benefit from immunotherapy, allowing more personalized treatment decisions.
- What could go wrong
- This is an early observational study, not a treatment trial. The test may not reliably predict outcomes, and results may not apply to all cancer types or treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?